Research grant empowers future leaders in clinical research to advance breakthroughs in the prevention, detection, diagnosis and treatment of NMIBC Two fellows to receive SUO NMIBC research grants through educational grant from Ferring Pharmaceuticals Schaumburg, Ill and Parsippany, NJ – December 02, 2025 – The Society of Urologic Oncology (SUO) and Ferring Pharmaceuticals today announced the SUO NMIBC (non-muscle invasive bladder […]

Parsippany, NJ – November 12, 2025 – Ferring Pharmaceuticals thanks New Jersey and Michigan for recognizing November as Clostridioides difficile (C. diff) Infection Awareness Month. The proclamations raise important awareness of the severe impact of C. diff infection, a serious and potentially deadly infection. This is the sixth consecutive year the office of New Jersey Governor Phil Murphy demonstrated commitment […]

Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled in the ADSTILADRIN in BLadder CancEr (ABLE)-41 real-world study Independent analysis based on billing records to report on the durability of ADSTILADRIN use in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder […]